phrykt

NextCure, Inc. (NXTC): who owns it and who trades it

As of Nov 16, 2026, NXTC insiders reported 1 open-market sale worth $185K and 18 purchases worth $1.8M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (Other), with $185K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling NextCure

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, NXTC insiders reported $1.8M of open-market purchases and $185K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.8M
18 trades, 1 people
Sales, 12 months
$185K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$1.6M$1.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026ADAR1 Capital Management, LLC +110% ownerPurchase12,333$5.10$62.9KForm 4
Nov 6, 2026ADAR1 Capital Management, LLC +110% ownerPurchase3,662$5.10$18.7KForm 4
Nov 5, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1,024$5.10$5.2KForm 4
Oct 27, 2026ADAR1 Capital Management, LLC +110% ownerPurchase3,553$5.10$18.1KForm 4
Oct 26, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1,672$5.03$8.4KForm 4
Oct 23, 2026ADAR1 Capital Management, LLC +110% ownerPurchase5,626$4.83$27.2KForm 4
Aug 10, 2026Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. +5OtherSale30,000$6.16$185KForm 4
Jul 31, 2026ADAR1 Capital Management, LLC +110% ownerPurchase8,003$4.80$38.4KForm 4
Jul 31, 2026ADAR1 Capital Management, LLC +110% ownerPurchase3,300$4.98$16.4KForm 4
Jul 31, 2026ADAR1 Capital Management, LLC +110% ownerPurchase25,000$4.98$125KForm 4
Jul 30, 2026ADAR1 Capital Management, LLC +110% ownerPurchase50,000$4.97$248KForm 4
Jul 30, 2026ADAR1 Capital Management, LLC +110% ownerPurchase20,000$5.00$100KForm 4
Jul 30, 2026ADAR1 Capital Management, LLC +110% ownerPurchase25,000$4.81$120KForm 4
Jul 30, 2026ADAR1 Capital Management, LLC +110% ownerPurchase77,850$4.96$386KForm 4
Jul 30, 2026ADAR1 Capital Management, LLC +110% ownerPurchase100,000$4.90$490KForm 4
Jul 29, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1,810$5.00$9.1KForm 4
Jul 29, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1,600$5.00$8KForm 4
Jul 28, 2026ADAR1 Capital Management, LLC +110% ownerPurchase6,400$4.95$31.7KForm 4
Jul 27, 2026ADAR1 Capital Management, LLC +110% ownerPurchase7,798$5.00$39KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
ADAR1 Capital Management, LLC10% owner$1.8M–Nov 11, 2026
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.Other–$185KAug 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NXTC short interest

Low short interest. 4.0% of NXTC shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went up 217%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 184,029 NXTC shares were sold short, 4.0% of the shares outstanding, down 16.7% from the report before. At the average daily volume of 61,907 shares, buying them all back would take about 3.0 trading days (days to cover).

Shares short, % of all shares

4.02%May 15Oct 3042.0%

Days to cover

3.0May 15Oct 303.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026184,0294.02%-17%61,9073.0
Oct 15, 2026220,9664.83%+4%74,7603.0
Sep 30, 2026213,3094.66%+103%114,7751.9
Sep 15, 2026105,2402.30%+128%99,5351.1
Aug 31, 202646,0661.01%-69%115,7781.0
Aug 14, 2026148,1363.24%+5%424,3141.0
Jul 31, 2026141,2483.09%-89%862,1821.0
Jul 15, 20261.32M36.65%+735%11.13M1.0
Jun 30, 2026158,5924.39%-30%129,7691.2
Jun 15, 2026225,5456.24%+228%217,6011.0
May 29, 202668,6871.90%+18%48,9161.4
May 15, 202658,0191.61%-20%33,1101.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

NextCure company events

NextCure filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, control). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 30, 2026LeadershipOn October 26, 2026 NextCure, Inc. determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief Medical Officer and a named executive officer of the Company, will be terminated effective October 31, 2026, in contemplation of the pending merger of the Company and Avere Therapeutics, Inc. ​… Filing
  3. Sep 25, 2026AnnouncementNextCure, Inc. filed a petition in the Delaware Court of Chancery pursuant to Section 205 of the Delaware General Corporation Law seeking validation of the Certificate of Amendment to the Company’s Third Amended and Restated Certificate of Incorporation that the Company filed with the Delaware… Filing
  4. Sep 3, 2026AgreementNextCure, Inc. and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 with respect to the Company's remaining approximately 29,864 rentable square feet of leased laboratory and office space located at 8000 Virginia Manor… Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jul 14, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  7. Jun 25, 2026LeadershipThe stockholders of NextCure, Inc. approved the amendment and restatement of the NextCure, Inc. 2019 Omnibus Incentive Plan at the Company’s 2026 Annual Meeting of Stockholders. Filing
  8. Jun 1, 2026AnnouncementCompany announced data from its Phase 1 dose escalation study (NCT06792552) evaluating SIM0505 in a multicenter, first in human global study in patients with advanced solid tumors. Filing
  9. May 7, 2026ResultsReleased financial results. Filing
  10. Mar 5, 2026ResultsReleased financial results. Filing
  11. Jan 23, 2026AnnouncementHereof, the information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not incorporated by reference into… Filing
  12. Dec 19, 2025AnnouncementNextCure, Inc. entered into an at the market offering agreement with H.C. Wainwright & Co., LLC, pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $14.5 million of its common stock, $0.001 par value per share, through the Agent. Filing
  13. Nov 17, 2025AgreementNextCure, Inc. entered into a securities purchase agreement with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for a private placement of an aggregate of (i) 708,428 shares of the Company’s common stock, par value $0.001 per share, at a… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

NextCure financials

Famous investors that hold NXTC

3 of the 50 well-known investors we track reported holding NXTC in their latest 13F filing. The largest position is Ken Griffin's, worth $554K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026110,660$554K0.0%New
Jim Simons · Renaissance TechnologiesQ3 202639,148$196K0.0%-77%
Israel Englander · Millennium ManagementQ3 202626,526$133K0.0%-70%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named NXTC in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Ikarian Capital, LLC13G/A9.8%
Nov 16, 2026Ikarian Capital, LLC13G/A9.8%
Nov 13, 2026Affinity Asset Advisors, LLC13G/A10.0%
Nov 13, 2026Affinity Asset Advisors, LLC13G/A10.0%
Oct 20, 2026JP Sailing Capital Ltd13G9.9%
Oct 20, 2026JP Sailing Capital Ltd13G9.9%

Questions about NextCure, Inc. (NXTC) stock

Are NXTC insiders buying or selling?

In the last 12 months, NXTC insiders reported 18 open-market purchases worth $1.8M and 1 sale worth $185K. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in NXTC?

As of Oct 30, 2026, 184,029 NXTC shares were sold short, 4.0% of the shares outstanding, down 16.7% from the report before. At the average daily volume of 61,907 shares, buying them all back would take about 3.0 trading days (days to cover). See the history.

Which famous investors hold NXTC?

3 of the 50 well-known investors we track reported NXTC in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $554K. See all holders.

Executive pay

NextCure's chief executive was paid a total of $942K for the year ended Dec 31, 2025, down 38% from $1.5M the year before. In the last 12 months, NextCure's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$942KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$636KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.